NewsRoom Articles - Page 68 of 154 - PsychedelicNewsWire (PNW)

TuesdayFeb 22, 2022 2:28 pm

Insights into Life and Psychedelics from Psychedelics Pioneers

Psychedelics pioneers have for many years argued that the substances enhance perception in a way that is healing and extraordinary. Below are powerful insights into human nature from a couple of psychonaut academics, writers and philosophers. Anaïs Nin Anaïs Nin was a French-Cuban-American writer who was consulted by doctors to improve their understanding of LSD’s effects. Nin participated in an LSD experiment in the fall of 1955, which was carried out by Oscar Janiger, an experimental psychiatrist best known for his research on LSD. Nin described the experience as the most pleasurable sensation she’d ever known, noting that it was…

TuesdayFeb 22, 2022 9:00 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Seeks to Capitalize on the Growing Market for Psychedelics in Healthcare

The global psychedelics market is estimated to hit $10.75 billion in 2027, with the alternative antidepressant drug market being valued at $15.98 billion in 2023 Already, 65% of individuals dealing with PTSD, depression, and anxiety in the United States believe that psychedelic medicine should be made available 83% of Americans living with these conditions are open to trying out alternative treatments Delic seeks to capitalize on this growing demand for psychedelic alternatives, coupled with ongoing legislative and regulatory changes to grow its brand and increase value for its shareholders While the psychedelics industry might be in its early stages, its…

FridayFeb 18, 2022 1:04 pm

Study Finds That Psychedelics Can Alter Core Metaphysical Beliefs

A new study has found that psychedelic substances can alter an individual’s core beliefs about the nature of free will, consciousness and reality. The study’s findings were reported in the “Scientific Reports” journal. The researchers’ objective was to find out whether psychedelics had the capacity to change a person’s core metaphysical beliefs, because the drugs can induce spiritual encounters and transformative experiences. Metaphysical beliefs are ideas about reality’s fundamental nature. The study was carried out by a team of researchers led by Christopher Timmermann, who examined the metaphysical beliefs of participants before and after they had used psychedelics. The researchers…

ThursdayFeb 17, 2022 10:15 am

Maryland Senators File Measure to Offer Veterans Free Access to Psychedelics

Earlier this week, a group of senators in the state of Maryland filed a measure which would establish a fund that could be used to support research into the therapeutic potential of psychedelics. The bill also called for providing free access to psychedelic drugs such as ketamine, MDMA and psilocybin for military veterans with PTSD. The bill, which was sponsored by Sen. Sarah Elfreth, would create a PTSD Alternative Therapies fund. The state fund would finance studies on psychedelics through Maryland’s Department of Health as well as offer cost-free access to alternative therapies. The measure stipulates that regulators will have…

WednesdayFeb 16, 2022 3:08 pm

Advocates Challenge DEA’s Proposal to Schedule Five Psychedelic Compounds

Researchers and advocates are challenging the DEA’s proposal to classify a series of psychedelic compounds under Schedule I of the Controlled Substances Act. The Drug Enforcement Administration published a scheduling proposal in the Federal Register in January that highlights its plan to ban the following tryptamines: DiPT, 5-MeO-DET, 5-MeO-MiPT, 5-MeO-AMT and 4-OH-DiPT. The DEA wants to classify these tryptamines under the same category as drugs such as LSD, cannabis and heroin. The agency stated that before it made the proposal, it conducted its own analyses as well as considered research and recommendations from the Department of Health and Human Services,…

TuesdayFeb 15, 2022 3:08 pm

Utah House Committee Approves Measure Allowing Research on Mental Health Benefits of Psychedelics

Last week, a House committee in the state of Utah passed a measure that would establish a task force to conduct research on and give recommendations for the therapeutic potential of psychedelic substances and regulations governing their legal use. The bill, which was sponsored by Rep. Brady Brammer, was approved by the House Health and Human Services Committee in a 10-to-1 vote. The bill stipulates that the task force would be required to research and give recommendations on drugs that could assist in mental illness treatment. The drugs to be considered included controlled substances that had the potential to manage,…

TuesdayFeb 15, 2022 9:30 am

Identified Psilocybin and MDMA Supplier, New Addition Strengthens Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) Board Experience

Biotechnology company Mydecine Innovations Group is devoted to advancing the use of psychedelics for the treatment of mental illnesses and addiction Mydecine has necessary license to provide psilocybin and MDMA under Canada’s SAP program, which allows medical providers to request otherwise unavailable drug substances for the treatment of patients who have not seen success with available treatment options The license allows Mydecine to provide psilocybin and MDMA (Ecstasy) through its licensed Alberta facility and collaboration with non-profit drug development institute Applied Pharmaceutical Innovation The company has named pharmaceutical scientist and entrepreneur Dr. Victoria Hale to its Board of Directors, strengthening…

TuesdayFeb 15, 2022 9:15 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Pushing the Conversation on Psychedelics and Access to Psychedelic Treatments for Persons Living with Mental Health Conditions

Delic seeks to bring mental health treatment closer to the people through an aggressive expansion plan In a study conducted by The Harris Poll on behalf of the company, it was noted that 65% of Americans dealing with mental health conditions believe that psychedelic medicine should be made available Studies such as these are helping Delic drive the conversation on psychedelics forward The company seeks to take this conversation further with its participation at this year’s Emerald Conference Over 51.5 million people have experienced a mental health condition in the United States alone, with the figures rising owing to the…

MondayFeb 14, 2022 12:32 pm

What You Should Consider Before Investing in Psychedelics Space

The psychedelics industry is projected to grow at a compound annual growth rate of 14.5% in the short term, hitting $6.3 billion by 2026. Psychedelics present an attractive investment opportunity for any investors seeking to diversify their portfolio. However, like most major decisions in life, investing hard-earned money should be done with a lot of forethought and caution, especially when dealing with products that have a lot of room for growth, such as psychedelics. To help stake a profitable position in the burgeoning psychedelics space, potential investors will need to understand that experts’ expectations of psychedelics blowing up in the…

MondayFeb 14, 2022 9:15 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives IRB Approval for Kernel Flow Feasibility Study

Institution Review Board gives green light to study designed around Kernel’s quantitative neuroimaging technology Kernel Flow device provides ability to measure longitudinal brain activity before, during and after a psychedelic experience CYBN CEO says results from study will further support company’s mission to develop psychedelics into therapeutics Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has received approval to move forward on a key feasibility study designed to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics (https://ibn.fm/f0HXk). The approval, granted by the Institution Review Board (“IRB”), gives a green light to a Cybin-sponsored study…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000